These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [STUDY ON LIVER TOLERANCE TO N-(4-MORPHOLINOMETHYL-PYRAZINAMIDE) IN THE TREATMENT OF PULMONARY TUBERCULOSIS]. BARRAS G Ther Umsch; 1964 Oct; 21():398-9. PubMed ID: 14323357 [No Abstract] [Full Text] [Related]
23. [EXPERIENCES WITH SPECIFIC CHEMOTHERAPY OF PULMONARY TUBERCULOSIS]. LEHR G Beitr Klin Tuberk Spezif Tuberkuloseforsch; 1964 May; 128():218-41. PubMed ID: 14217711 [No Abstract] [Full Text] [Related]
24. [HEMORRHAGIC PURPURA IN THE COURSE AND CHEMO-ANTIBIOTIC THERAPY OF PULMONARY TUBERCULOSIS]. CIMINO A Gazz Int Med Chir; 1963 Dec; 67():SUPPL:3572-84. PubMed ID: 14177589 [No Abstract] [Full Text] [Related]
25. [INFECTIOUS HEPATITIS AND THE PROBLEMS OF LIVER TISSUE DAMAGE CAUSED BY ANTITUBERCULAR AGENTS]. PROCHAZKA J; VANISTA J; SEIDLER L; KUERTI V; ENGLIS M Z Arztl Fortbild (Jena); 1964 Aug; 58():859-62. PubMed ID: 14308631 [No Abstract] [Full Text] [Related]
27. SOME PROBLEMS IN THE MANAGEMENT OF TUBERCULOSIS. MITCHELL JH Br J Clin Pract; 1964 Feb; 18():63-8. PubMed ID: 14115576 [No Abstract] [Full Text] [Related]
28. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. Gray EL; Goldberg HF Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478 [TBL] [Abstract][Full Text] [Related]
30. [MYXEDEMA IN THE COURSE OF ANTITUBERCULOSIS THERAPY]. MARCHESE MJ; BERTORELLO MC; CARDOZO E Rev Asoc Med Argent; 1963 Nov; 77():542-4. PubMed ID: 14108781 [No Abstract] [Full Text] [Related]
31. THE PROBLEM AND MANAGEMENT OF DRUG-RESISTANT CASES OF PULMONARY TUBERCULOSIS IN KENYA. ANGAWA JO East Afr Med J; 1964 Sep; 41():436-40. PubMed ID: 14229818 [No Abstract] [Full Text] [Related]
32. ORAL CONTRACEPTIVES AND LIVER DAMAGE. BORGLIN NE Br Med J; 1965 May; 1(5445):1289-90. PubMed ID: 14278822 [No Abstract] [Full Text] [Related]
33. [3 CASES OF POISONING IN CHILDHOOD WITH IRGAPYRIN, BUTAZOLIDIN AND TOMANOL]. KOWALEWSKI S; ROTTHAUWE HW; HAUKE H Ann Paediatr; 1964; 202():43-57. PubMed ID: 14112916 [No Abstract] [Full Text] [Related]
34. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)]. Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070 [TBL] [Abstract][Full Text] [Related]
35. TREATMENT OF ISONIAZID-RESISTANT TUBERCULOSIS. FISCHER DA; KASS I; DYE WE; LESTER W Antimicrob Agents Chemother (Bethesda); 1964; 10():699-707. PubMed ID: 14288022 [No Abstract] [Full Text] [Related]
36. [ENDOCRINE-METABOLIC COMPLICATIONS OF ANTIBACTERIAL CHEMOTHERAPY. ISONIAZID AND CUSHING'S SYNDROME]. VERGARAOLIVAS A Bull Int Union Tuberc; 1964 Sep; 35():142-6. PubMed ID: 14269362 [No Abstract] [Full Text] [Related]
38. [TEBAFEN IN THE TREATMENT OF TUBERCULOSIS IN CHILDREN]. GLOWACKA M; GRZYBOWSKA J Wiad Lek; 1965 Mar; 18():487-90. PubMed ID: 14315501 [No Abstract] [Full Text] [Related]
39. TOXIC MANIFESTATIONS DUE TO ANTITUBERCULOUS DRUGS IN TUBERCULOUS PATIENTS TREATED FROM 1-12 YEARS. SIRCAR DK Indian J Chest Dis; 1965 Jan; 7():40-6. PubMed ID: 14332629 [No Abstract] [Full Text] [Related]
40. STUDIES WITH A NEW ANTITUBERCULOSIS DRUG. SEN NN J Indian Med Assoc; 1964 Nov; 43():417-9. PubMed ID: 14227456 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]